Indane Derivatives as Selective HIF-2α Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with HIF-2α, such as renal cell carcinoma, lack effective inhibitors that specifically target HIF-2α without affecting HIF-1α, leading to inadequate therapeutic outcomes.
Innovation Solution
Development of specific compounds, including those of Formula IV and Formula I, which act as HIF-2α inhibitors by reducing HIF-2α signaling output, heterodimerization with ARNT, and regulation of target gene expression, thereby selectively inhibiting HIF-2α without affecting HIF-1α.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current treatments are used for HIF-2α associated conditions, then general HIF inhibition may occur, but specific HIF-2α inhibition without affecting HIF-1α is not achieved
Solution Approach 1:
The invention segments the HIF inhibition function by designing compounds that specifically target HIF-2α while leaving HIF-1α unaffected. This is achieved through selective binding to the PAS-B domain of HIF-2α, creating a differentiated inhibition strategy that addresses the contradiction between specificity and therapeutic reliability.
Solution Approach 2:
The compounds exhibit local quality by demonstrating selective affinity for HIF-2α over HIF-1α. The molecular structure is designed to interact specifically with HIF-2α's PAS-B domain, creating a localized inhibitory effect that spares HIF-1α-mediated physiological functions while targeting HIF-2α-associated pathologies.
2Productivity
If HIF-2α signaling is inhibited to reduce tumor growth, then therapeutic benefit is achieved, but lack of selective compounds limits treatment effectiveness
Solution Approach 1:
The invention applies parameter changes by modifying molecular structure parameters to achieve selective HIF-2α inhibition. The compounds feature specific structural elements (such as the hydroxynaphthalene moiety and dibenzofuran-dione core) that tune the binding affinity and selectivity parameters, enabling effective tumor growth inhibition while addressing the scarcity of selective inhibitors.
3Adaptability or versatility
If general HIF inhibition is used, then broad pathway suppression occurs, but selective HIF-2α targeting without HIF-1α affectation is not achieved
Solution Approach 1:
The compounds act as intermediaries that selectively mediate between the therapeutic goal (HIF-2α inhibition) and the biological system. The molecular structure serves as a precise mediator that binds to HIF-2α's PAS-B domain, enabling selective pathway modulation without requiring complex multi-component systems.
Data Source
AI summary
Disclosed herein are substituted indane derivatives useful as HIF-2α inhibitors. Pharmaceutical compositions comprising said indane derivatives and methods of using said indane derivatives for treating proliferative diseases, such as renal cell carcinoma and von Hippel-Lindau disease, and other conditions associated with HIF-2α activity are also disclosed.